Cantor Fitzgerald Estimates Zai Lab FY2026 Earnings

Zai Lab Limited (NASDAQ:ZLAB - Free Report) - Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Zai Lab in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings per share of $1.38 for the year. Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Zai Lab's current full-year earnings is ($2.58) per share.

Several other equities analysts have also recently weighed in on ZLAB. Scotiabank initiated coverage on shares of Zai Lab in a research note on Friday, March 7th. They set a "sector outperform" rating and a $55.00 price target for the company. Bank of America reaffirmed a "neutral" rating and set a $36.10 price target (up from $29.00) on shares of Zai Lab in a research note on Monday, March 3rd. Finally, JPMorgan Chase & Co. raised their price target on shares of Zai Lab from $44.00 to $51.00 and gave the stock an "overweight" rating in a research note on Thursday, March 13th.

Zai Lab Price Performance

Shares of ZLAB traded down $2.03 during mid-day trading on Wednesday, hitting $41.00. 1,019,212 shares of the company's stock were exchanged, compared to its average volume of 897,658. The company has a market cap of $4.52 billion, a PE ratio of -14.80 and a beta of 0.96. Zai Lab has a 52 week low of $16.01 and a 52 week high of $44.34. The company has a 50-day simple moving average of $31.78 and a 200 day simple moving average of $30.52.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.05. The firm had revenue of $106.49 million for the quarter, compared to the consensus estimate of $118.40 million. Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%.

Insider Activity at Zai Lab

In related news, CFO Yajing Chen sold 924 shares of the firm's stock in a transaction on Friday, April 4th. The shares were sold at an average price of $33.11, for a total value of $30,593.64. Following the completion of the transaction, the chief financial officer now directly owns 27,047 shares of the company's stock, valued at approximately $895,526.17. This trade represents a 3.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Rafael Amado sold 3,000 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $38.41, for a total transaction of $115,230.00. Following the completion of the transaction, the insider now directly owns 30,834 shares of the company's stock, valued at $1,184,333.94. This represents a 8.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 130,207 shares of company stock valued at $3,880,239. 4.96% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Zai Lab

Several hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC grew its stake in shares of Zai Lab by 749.1% in the fourth quarter. FMR LLC now owns 5,475,505 shares of the company's stock valued at $143,403,000 after buying an additional 4,830,646 shares in the last quarter. Principal Financial Group Inc. boosted its position in Zai Lab by 63.6% during the first quarter. Principal Financial Group Inc. now owns 2,884,810 shares of the company's stock worth $104,257,000 after purchasing an additional 1,121,856 shares during the period. RTW Investments LP bought a new position in Zai Lab during the fourth quarter worth $65,714,000. Price T Rowe Associates Inc. MD boosted its position in Zai Lab by 30.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,354,025 shares of the company's stock worth $61,653,000 after purchasing an additional 548,378 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Zai Lab by 46,222.0% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,132,201 shares of the company's stock worth $77,058,000 after purchasing an additional 2,127,598 shares during the period. 41.65% of the stock is owned by institutional investors.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.